Logo
Sculptra® 2 x 5 ml Vials

Sculptra® 2 x 5 ml Vials

Sculptra®

Medical device – Biostimulatory dermal filler
  • CE‑marked medical device (PLLA injectable; marketed in EU/UK under regulatory conformity per manufacturer). :contentReference[oaicite:32]{index=32}
  • Approved by the U.S. Food and Drug Administration (FDA) for facial volume restoration and correction of facial lipoatrophy / fat loss in approved indications. :contentReference[oaicite:34]{index=34}
Poly\u2011L\u2011lactic acid (PLLA) collagen stimulator for facial volume restoration

Description

Sculptra® is an injectable biostimulatory filler containing microparticles of poly‑L‑lactic acid (PLLA), supplied as sterile lyophilised powder in vials which must be reconstituted with sterile water before injection. Once injected into deep dermis, subcutaneous or supraperiosteal plane, the PLLA microparticles stimulate neocollagenesis and gradually restore facial volume, smoothing wrinkles, folds and correcting signs of facial fat loss or ageing. Results build slowly over weeks to months for a natural-looking volume restoration. :contentReference[oaicite:2]{index=2}

Bnefits

  • Stimulates natural collagen production (type I / III) leading to gradual volume restoration rather than immediate ‘fill’. :contentReference[oaicite:3]{index=3}
  • Provides long‑lasting results: effect duration up to 24 months with full treatment protocol (multiple sessions), per regulatory summary. :contentReference[oaicite:4]{index=4}
  • Suitable for correcting volume loss from ageing, facial fat loss (e.g. lipoatrophy), deep wrinkles and folds, hollowness or depressed areas. :contentReference[oaicite:5]{index=5}
  • Biocompatible and biodegradable synthetic polymer (PLLA) — not derived from human or animal tissue, reducing allergy risk. :contentReference[oaicite:6]{index=6}

Indications

  • Correction of shallow to deep nasolabial fold contour deficiencies and other facial wrinkles. :contentReference[oaicite:7]{index=7}
  • Correction of fine lines and wrinkles in the cheek region. :contentReference[oaicite:8]{index=8}
  • Restoration and/or correction of facial fat loss (lipoatrophy), and treatment of facial volume deficiencies due to ageing. :contentReference[oaicite:9]{index=9}
  • Large‑volume corrections where volume restoration rather than superficial filling is desired (e.g. cheeks, temples, jawline, chin). :contentReference[oaicite:10]{index=10}

Composition

  • Poly‑L‑lactic acid (PLLA) 150 mg per vial (lyophilised powder). :contentReference[oaicite:11]{index=11}
  • Sodium carboxymethylcellulose 90 mg per vial (suspension agent). :contentReference[oaicite:12]{index=12}
  • Non‑pyrogenic mannitol 127.5 mg per vial (stabilizer). :contentReference[oaicite:13]{index=13}

Formulation

  • Sterile, non‑pyrogenic freeze‑dried powder (lyophilised) supplied in glass vials for reconstitution. :contentReference[oaicite:14]{index=14}
  • Upon reconstitution with 5–8 ml sterile water for injection (plus optional lidocaine for comfort), forms a sterile suspension of PLLA microparticles for injection. :contentReference[oaicite:15]{index=15}

Packaging

  • Box containing 2 vials (each 5 ml freeze‑dried powder). Example retail presentation: 2 × 5 ml vials for professional use only. :contentReference[oaicite:16]{index=16}
  • Each vial sealed in sterile glass vial with rubber stopper and flip‑off cap; outer carton labelled with product name, batch/lot, manufacturer, instructions for use (IFU) per regulatory requirements. :contentReference[oaicite:17]{index=17}

Usage

  • Reconstitute each vial with 5–8 ml of sterile water for injection to form a sterile suspension before use. Optionally add up to 1 ml of 2% lidocaine solution for comfort. :contentReference[oaicite:18]{index=18}
  • Inject only by trained, licensed healthcare practitioners experienced in PLLA injections. Use sterile single‑use syringes and 25G or 26G needles; injection depth: deep dermis, subcutaneous layer or supraperiosteal plane as appropriate. :contentReference[oaicite:19]{index=19}
  • Do not overcorrect in first session — gradual volume increase expected over weeks. Re‑evaluate no sooner than four weeks before additional sessions. :contentReference[oaicite:20]{index=20}

Contraindications

  • Hypersensitivity to any component of the product. :contentReference[oaicite:23]{index=23}
  • History of keloid formation or hypertrophic scarring. :contentReference[oaicite:24]{index=24}
  • Active skin disease, infection, inflammation, or acne in the treatment area — postpone until resolved. :contentReference[oaicite:25]{index=25}
  • Injection into the red area (vermillion) of lip or peri‑orbital area is contraindicated. :contentReference[oaicite:26]{index=26}
  • Not established for use in under-18s, pregnant or breastfeeding individuals. :contentReference[oaicite:27]{index=27}

Adverse Effects

  • Common local reactions: swelling, redness, tenderness, pain, bruising, bleeding, itching at injection site. :contentReference[oaicite:28]{index=28}
  • Small lumps or nodules under the skin — sometimes noticeable on pressure; larger or delayed-onset nodules reported, may occur with or without inflammation or skin discoloration. :contentReference[oaicite:29]{index=29}

Storage Conditions

  • Store lyophilised vials at controlled room temperature (as per manufacturer label) before reconstitution. :contentReference[oaicite:30]{index=30}
  • After reconstitution, use promptly as per IFU; do not store reconstituted suspension beyond recommended period (as per Instructions for Use). :contentReference[oaicite:31]{index=31}

Duration

With full treatment course (multiple sessions), effect may last up to 24 months (2 years) per clinical data and FDA summary. :contentReference[oaicite:21]{index=21}

Onset

Gradual onset: improvements begin in weeks (often visible around 4\u20136 weeks), and build over 2\u20134 months as new collagen forms. :contentReference[oaicite:22]{index=22}

Browse more Medical device \u2013 Biostimulatory dermal filler

Top Treatments

Top Cities in the UK